Erratum to: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis (Nature Medicine, (2018), 24, 11, (1708-1715), 10.1038/s41591-018-0224-2);A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Nature Medicine

Volumn 24, Issue 11, 2018, Pages 1708-1715

  Imperial, Marjorie Z ^a   Nahid, Payam ^a   Phillips, Patrick P J ^a   Davies, Geraint R ^b   Fielding, Katherine ^c   Hanna, Debra ^d,e   Hermann, David ^e   Wallis, Robert S ^f   Johnson, John L ^g,h   Lienhardt, Christian ^i,j   Savic, Rada M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d CRITICAL PATH INSTITUTE   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f AURUM INSTITUTE   (South Africa)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j UNIVERSITÉ DE MONTPELLIER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85056146022     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0294-1     Document Type: Erratum

References (22)

1. Merle, C. S. et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588–1598 (2014)
2. Gillespie, S. H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577–1587 (2014)
3. Jindani, A. et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599–1608 (2014)
4. World Health Organization. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update (World Health Organization, Geneva, 2017)
5. Nahid, P. et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin. Infect. Dis. 63, e147–e195 (2016)
6. Jo, K.-W. et al. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir. Med. 108, 654–659 (2014)
7. Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528–534 (2002)
8. Goldberg, S. TBTC Study 31: rifapentine-containing tuberculosis treatment shortening regimens (S31/A5349). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02410772 (2015)
9. Johnson, J. L. et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am. J. Respir. Crit. Care Med. 180, 558–563 (2009)
10. Savic, R. M. et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin. Pharmacol. Ther. 102, 321–331 (2017)
11. Alipanah, N. et al. Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis. Int. J. Tuberc. Lung Dis. 20, 1522–1528 (2016)
12. Vernon, A. A. & Iademarco, M. F. In the treatment of tuberculosis, you get what you pay for.. Am. J. Respir. Crit. Care Med. 170, 1040–1042 (2004)
13. Chang, K. C., Leung, C. C., Yew, W. W., Ho, S. C. & Tam, C. M. A nested case–control study on treatment-related risk factors for early relapse of tuberculosis. Am. J. Respir. Crit. Care Med. 170, 1124–1130 (2004)
14. Ngwatu, B. K. et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur. Respir. J. 51, 1701596 (2018)
15. DiStefano, M. J. & Schmidt, H. mHealth for tuberculosis treatment adherence: a framework to guide ethical planning, implementation, and evaluation. Glob. Health Sci. Pract. 4, 211–221 (2016)
16. Fox, W., Ellard, G. A. & Mitchison, D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3, S231–S279 (1999)
17. Fox, W. Whither short-course chemotherapy? Br. J. Dis. Chest 75, 331–357 (1981)
18. Kendall, E. A. et al. Priority-setting for novel drug regimens to treat tuberculosis: an epidemiologic model. PLoS Med. 14, e1002202 (2017)
19. Clinical Data Interchange Standards Consortium. CDISC Therapeutic Area Data Standards User Guide for Tuberculosis (Version 2.0). https://www.cdisc.org/standards/therapeutic-areas/tuberculosis (2016)
20. Taichman, D. B. et al. Sharing clinical trial data—a proposal from the International Committee of Medical Journal Editors. N. Engl. J. Med. 374, 384–386 (2016)
21. Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J. & Drazen, J. M. Statistics in medicine—reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357, 2189–2194 (2007)
22. Xie, J. & Liu, C. Adjusted Kaplan–Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat. Med. 24, 3089–3110 (2005)